The treatment of macular degeneration is in the midst of a remarkable period of innovation. It is an exciting time to be an eyecare professional. As detailed in Part 1 of this synopsis (ProFile, September 2013), neovascular age-related macular degeneration (nvAMD) has a natural history of profound central vision loss. However, the last 10 years has seen the advent of new agents that have dramatically improved the prognosis of this condition. Further developments are presently being investigated in both neovascular and non-neovascular variants of the disease. This article will discuss the previous, current and possible future treatments. Despite the advances, certain clinical scenarios remain better suited to ‘older’ treatments. Plus, it is important that we remember that with increased capacity for treatment, there is an increased onus on early detection.
Share, Print or Favourite